Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06799117 · ClinicalTrials.gov registry record · NA
Adaptive Decision Support for Addiction Treatment Master
A NA study of Opioid Use Disorder, sponsored by Yale University.
- Recruiting
- Registry status
- NA
- Development phase
- 1,912
- Enrollment target
- 3
- Study locations
NCT06799117: Recruiting NA study of Opioid Use Disorder, sponsored by Yale University.
NCT06799117 is a NA study of Opioid Use Disorder that is actively recruiting participants, run by Yale University. The registered enrollment target is 1,912 participants, below the 4,649-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (59% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06799117, a NA study of Opioid Use Disorder, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- NA
- Development phase
- 1,912 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study refines and optimizes the EMBED\* clinical decision support (CDS; see NCT03658642) to increase number of ED physicians following standard of care for the administration of buprenorphine to appropriate patients with opioid use disorder. This study does not have open enrollment. Investigators will use a Multiphase Optimization STrategy (MOST) framework study with preparation, optimization, and confirmatory phases. Optimization Phase: This phase has two stages. In stage 1, investigators will conduct a 2x2x2 factorial trial to expand EMBED is expanded to include sustainable implementation strategies: nurse prompt for withdrawal assessment, and targeted clinician prompts to use the CDS along with individualized patient resources to promote equity and motivate readiness to start treatment. In Stage 2, investigators will improve CDS usability via serial randomized testing to inform iterative refinement of the CDS interface and workflow to minimize user errors, task disruption, and abandonment through identification of specific targets for improvement via application of novel CDS outcome measures in serial randomized tests. Evaluation phase: Investigators will conduct a randomized trial to compare the efficacy effectiveness of the optimized package compared to the original on ED-initiation of buprenorphine rates in patients with OUD. \*EMBED is a user user-centered, clinician clinician-facing clinical decision support system integrated into the electronic health record workflow to facilitate initiating buprenorphine in the emergency department by: diagnosing opioid use disorder with a checklist based on the diagnostic criteria of the DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, fifth edition), assessing the severity of withdrawal with the Clinical Opioid Withdrawal Scale (COWS), motivating patients to accept treatment with a scripted brief negotiation interview, and automating the electronic health record workflow, including clinical and afte
Primary Outcome
Proportion of eligible encounters with buprenorphine administered in the Emergency Department (ED) and/or prescribed buprenorphine on discharge from the ED. Obtained from EHR data.
Conditions Studied
Interventions
- OTHER EMBED CDS
- OTHER Nurse prompt to complete COWS
- OTHER Provider Prompt
- OTHER Patient facing materials
- OTHER Optimized EMBED
Study Locations (3)
Connecticut
- Yale New Haven Shoreline Medical Center - Guilford
- Yale New Haven Hospital- St. Raphael - New Haven
- Yale New Haven Hospital - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,912 participants |
| Start Date | 2025-03-21 |
| Est. Completion | 2028-03-31 |
| Phase | NA |
What NCT06799117 shows while recruiting
NCT06799117 is an interventional study that assigns participants to a tested intervention. Its 1,912 participants enrollment target places it among the larger protocols in the corpus, below the 4,649-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (59% lower).
The record links to 1 condition, with Opioid Use Disorder appearing as the primary indexed condition, and to 5 interventions - of which EMBED CDS is the first listed.
NCT06799117 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT06799117 about?
NCT06799117 is a clinical study titled "Adaptive Decision Support for Addiction Treatment Master". This study refines and optimizes the EMBED\* clinical decision support (CDS; see NCT03658642) to increase number of ED physicians following standard of care for the administration of buprenorphine to appropriate patients with opioid use disorder. This study does not have open enrollment. Investigat...
What is the current status of trial NCT06799117?
This trial is currently recruiting. It is a NA study. The enrollment target is 1,912 participants. The study started on 2025-03-21. Estimated completion is 2028-03-31.
What conditions does trial NCT06799117 study?
This clinical trial studies the following conditions: Opioid Use Disorder.
What interventions are being tested in trial NCT06799117?
The interventions under investigation include: EMBED CDS (OTHER), Nurse prompt to complete COWS (OTHER), Provider Prompt (OTHER), Patient facing materials (OTHER), Optimized EMBED (OTHER).
Who is sponsoring clinical trial NCT06799117?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06799117 being conducted?
This trial has 3 study locations across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Opioid Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06799117's enrollment target sits among peer trials
1,912 11th of 257 higher than 247 of 257 other Opioid Use Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Opioid Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sustaining Recovery for People on Opioid Agonist Treatment With Conversational Agents
RECRUITING · NA
-
Development of an mHealth Behavioral Sleep Medicine Intervention for Use During Medication Assisted Treatment for MOUD
RECRUITING · NA
-
Systems Analysis and Improvement to Optimize Opioid Use Disorder Care Quality and Continuity for Patients Exiting Jail
RECRUITING · NA
-
Focused Ultrasound for the Complex Patient
RECRUITING · NA
-
Community-based Education, Navigation, and Support Intervention for Military Veterans
RECRUITING · NA
-
Using Facebook to Support Opioid Recovery Among American Indian Women
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05174169 · 1,912 participants · Phase 2
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
- NCT06058455 · 1,920 participants · NA
An Evaluation of an Online Sexual Assault Resistance Program (IDEA3)
- NCT03729180 · 1,900 participants · NA
The ImPreSS Trial: Pharmacogenomic Decision Making at Time of Surgery
- NCT05712200 · 1,900 participants · Phase 3
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI